Autobio Diagnostics Co., Ltd. (603658.SS)
CNY 44.66
(-3.17%)
CNY 44.66
(-3.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.36 Billion CNY | -8.76% |
| 2022 | 1.29 Billion CNY | 20.46% |
| 2021 | 1.07 Billion CNY | 25.66% |
| 2020 | 856.36 Million CNY | -4.24% |
| 2019 | 894.23 Million CNY | 36.75% |
| 2018 | 653.94 Million CNY | 29.19% |
| 2017 | 506.17 Million CNY | 28.33% |
| 2016 | 394.42 Million CNY | 26.41% |
| 2015 | 312.03 Million CNY | 33.95% |
| 2014 | 232.95 Million CNY | 73.2% |
| 2013 | 134.49 Million CNY | 27.28% |
| 2012 | 105.67 Million CNY | 55.12% |
| 2011 | 68.12 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 375 Million CNY | 29.1% |
| 2024 Q1 | 314.2 Million CNY | 2.2% |
| 2024 Q2 | 290.47 Million CNY | -7.55% |
| 2023 Q3 | 400.51 Million CNY | 19.53% |
| 2023 Q4 | 307.43 Million CNY | -23.24% |
| 2023 Q1 | 270.9 Million CNY | -0.25% |
| 2023 FY | 1.18 Billion CNY | -8.76% |
| 2023 Q2 | 335.06 Million CNY | 23.69% |
| 2022 Q4 | 271.59 Million CNY | -34.24% |
| 2022 Q3 | 413.02 Million CNY | 26.27% |
| 2022 Q1 | 284.65 Million CNY | 6.85% |
| 2022 FY | 1.29 Billion CNY | 20.46% |
| 2022 Q2 | 327.1 Million CNY | 14.91% |
| 2021 Q3 | 351.85 Million CNY | 32.58% |
| 2021 FY | 1.07 Billion CNY | 25.66% |
| 2021 Q1 | 192.5 Million CNY | -26.03% |
| 2021 Q2 | 265.38 Million CNY | 37.86% |
| 2021 Q4 | 266.4 Million CNY | -24.28% |
| 2020 Q3 | 279.61 Million CNY | 36.8% |
| 2020 FY | 856.36 Million CNY | -4.24% |
| 2020 Q1 | 112.09 Million CNY | -57.65% |
| 2020 Q2 | 204.4 Million CNY | 82.36% |
| 2020 Q4 | 260.25 Million CNY | -6.93% |
| 2019 Q3 | 252.9 Million CNY | 6.12% |
| 2019 Q2 | 238.32 Million CNY | 72.25% |
| 2019 FY | 894.23 Million CNY | 36.75% |
| 2019 Q4 | 264.65 Million CNY | 4.65% |
| 2019 Q1 | 138.36 Million CNY | -23.11% |
| 2018 Q3 | 187.06 Million CNY | 7.01% |
| 2018 Q4 | 179.94 Million CNY | -3.8% |
| 2018 FY | 653.94 Million CNY | 29.19% |
| 2018 Q1 | 112.1 Million CNY | -19.56% |
| 2018 Q2 | 174.81 Million CNY | 55.93% |
| 2017 Q3 | 153 Million CNY | 9.09% |
| 2017 FY | 506.17 Million CNY | 28.33% |
| 2017 Q4 | 139.37 Million CNY | -8.91% |
| 2017 Q1 | 73.53 Million CNY | -31.34% |
| 2017 Q2 | 140.25 Million CNY | 90.74% |
| 2016 Q1 | 60.55 Million CNY | -33.6% |
| 2016 Q3 | 122.35 Million CNY | 17.19% |
| 2016 Q4 | 107.1 Million CNY | -12.46% |
| 2016 Q2 | 104.4 Million CNY | 72.4% |
| 2016 FY | 394.42 Million CNY | 26.41% |
| 2015 Q1 | 60.97 Million CNY | 0.0% |
| 2015 Q3 | 97.54 Million CNY | 59.97% |
| 2015 Q4 | 91.2 Million CNY | -6.49% |
| 2015 FY | 312.03 Million CNY | 33.95% |
| 2015 Q2 | 60.97 Million CNY | 0.0% |
| 2014 FY | 232.95 Million CNY | 73.2% |
| 2013 FY | 134.49 Million CNY | 27.28% |
| 2012 FY | 105.67 Million CNY | 55.12% |
| 2011 FY | 68.12 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 646.8 Million CNY | -111.153% |
| Joinn Laboratories(China)Co.,Ltd. | 507.09 Million CNY | -169.327% |
| WuXi AppTec Co., Ltd. | 11.87 Billion CNY | 88.496% |
| Thalys Medical Technology Group Inc. | -180.32 Million CNY | 857.394% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 759.76 Million CNY | -79.76% |
| Chemclin Diagnostics Co., Ltd. | 166.28 Million CNY | -721.324% |